We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




High-Tech Method for Protein Biomarker Assay Testing to Revolutionize POC Diagnosis

By LabMedica International staff writers
Posted on 23 Jun 2022

An accessible universal solution to offer rapid personalized mobile testing for infectious diseases – or diagnosis and delivery of targeted treatments for other diseases even in remote areas – has so far been out of reach. More...

Now, a speedy high-tech method of inexpensive, accurate and high-throughput protein biomarker assay testing is being touted as a much-needed development in point-of-care (PoC) testing.

Researchers at Flinders University (Adelaide, Australia) who specialize in ‘green’ vortex fluidic device (VFD) medical applications have developed a VFD that can test for infectious diseases such as flu and COVID-19 within five minutes. The new method using the revolutionary VFD can be readily scaled up to test hundreds and ‘potentially thousands’ of proteins in one assay in less than five minutes. While many costly tests can take upwards of 48-72 hours, on-the-spot tests such as this can lead to accurate diagnosis and early commencement of important drug treatments and reduction of wrong medications.

In a trial, the new method, labeled VFD-accelerated immoblot assay (VAIA), was compared and found superior to other PoC biomarker-based tests currently in use. Not only was the processing faster and accurate, it sliced up to 70% off the cost of sometimes toxic reagents. While many immunoblot assays are used to detect certain diseases, many are not highly sensitive and complex to use – even for technicians in a laboratory or clinical setting. In contrast the VAIA was found to improve conventional processing time from hours to less than five minutes, using three major immunoassay formats with purified proteins and biofluids.

“Most importantly, the data produced can be accurately read with a cell phone camera – immediately addressing the gap between development and implementation of biomarker-based precision medicine,” said Professor Gregory Weiss, senior researcher from the University of California, who is a US leader in VFD experiments and applications.

“The extreme disparity between technologically lagging and advanced settings directly impacts disease mortality and morbidity, particularly for infectious diseases,” added Dr. Xuan Luo, a Flinders University researcher.

Related Links:
Flinders University 


New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Modular Hemostasis Automation Solution
CN Track
New
Rapid Test Reader
DIA5000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.